平安好醫生(01833.HK)與日健中外搭建骨質疏鬆患者全病程管理體系
平安好醫生(01833.HK)與日本製藥公司日健中外製藥達成戰略合作,共同啓動骨質疏鬆管理中心項目,搭建骨質疏鬆患者全病程管理創新體系,提升原創新藥可及性。
雙方將在藥品資源可及性、用藥指導管理、以及前沿學術成果共用等方面合作,使互聯網醫療全面賦能藥品,造福廣大病患。據瞭解,平安好醫生將與日健中外製藥聯合首發原創新藥。在藥品合作基礎上,平安好醫生將全程爲用戶提供定製化的解決方案,並透過及時追蹤健康數據、調整病程管理策略,以及深入真實世界研究,推動優質藥品普惠骨質疏鬆患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.